Route of Administration Segment Analysis: Oral (Largest Segment) vs Subcutaneous (Fastest-Growing Segment)

The immunotherapy drugs market was led by the oral segment, which accounted for 48.12% of the market share in 2026. Oral immunotherapy drugs are widely preferred because they offer greater convenience, improved treatment adherence, and ease of self-administration compared with injectable alternatives. The reduced need for clinical visits and simplified long-term treatment management make oral therapies particularly suitable for patients requiring continuous care. Ongoing development of targeted oral immunotherapies and increasing patient preference for convenient treatment options continue to reinforce the segment's leading position.

The subcutaneous segment is the fastest-growing route of administration as healthcare providers increasingly adopt therapies that combine clinical effectiveness with greater convenience. Subcutaneous administration can reduce treatment time, support outpatient and home-based care, and improve patient comfort compared with conventional infusion-based therapies. Growing demand for patient-centric treatment approaches and advances in drug delivery technologies continue to accelerate growth in this segment.

Application Segment Analysis: Cancer (Largest Segment) vs Autoimmune Diseases (Fastest-Growing Segment)

The cancer segment dominated the immunotherapy drugs market, accounting for 62.21% of the market share in 2026. Immunotherapy has become a fundamental treatment approach in oncology because it harnesses the body's immune system to recognize and eliminate cancer cells while offering durable therapeutic benefits in several malignancies. Expanding clinical adoption, continuous innovation in immuno-oncology, and increasing demand for targeted cancer treatments continue to strengthen the segment's dominant position.

The autoimmune diseases segment is witnessing the fastest growth as immunotherapy increasingly becomes an important strategy for regulating abnormal immune responses associated with chronic inflammatory disorders. Growing awareness of immune-mediated diseases, improved understanding of disease mechanisms, and continued development of targeted immunomodulatory therapies are expanding treatment opportunities. Rising demand for personalized therapies with improved safety and efficacy profiles is further supporting the segment's rapid growth.

Drug Type Segment Analysis: Monoclonal Antibodies (Largest Segment) vs Check Point Inhibitor (Fastest-Growing Segment)

The monoclonal antibodies segment accounted for 59.77% of the market share in 2026, making it the largest drug type in the immunotherapy drugs market. Monoclonal antibodies are extensively used across oncology, autoimmune diseases, and other immune-related conditions because of their ability to selectively target specific disease pathways while minimizing effects on healthy tissues. Their broad therapeutic applications, established clinical effectiveness, and continuous pipeline expansion continue to reinforce market leadership.

The check point inhibitor segment is the fastest-growing category as these therapies continue to transform cancer treatment by enhancing the immune system's ability to recognize and attack tumor cells. Increasing research activity, expanding therapeutic indications, and growing integration of checkpoint inhibitors into combination treatment strategies are driving broader clinical adoption. Continued advances in precision medicine and immuno-oncology are expected to sustain strong growth for this segment.